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tional 83% and 52% risk of hyperaemia respectively. Based on
the current meta-analyses, latanoprost treated patients had least
risk of developing hyperaemia and bimatoprost the highest risk.
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OBJECTIVES: To assess the cost-effectiveness of intermittent
therapy with etanercept at a starting dose of 25 mg twice a week
(biw) or 50 mg biw compared to efalizumab and non-systemic
therapy (NST) in patients with moderate-to-severe plaque pso-
riasis in France. METHODS: An economic model was developed
to estimate the incremental cost per quality-adjusted life-year
(QALY) gained. Patients considered had a Psoriasis Area Severity
Index (PASI) and a value of Dermatology Life Quality Index10
at baseline. Four therapeutic strategies were considered: 1)etan-
ercept given intermittently (until remission deﬁned by PASI 90 or
with maximum treatment period of 24 weeks) either 25 mg biw;
2)etanercept 50 mg biw for 12 weeks followed by 25 mg biw;
3)efalizumab 1 mg/kg once weekly; and 4)NST. Response rates
were taken from clinical trials for each agent and were extrapo-
lated to a time horizon of ten years using a Markov process.
Costs were estimated from the French Third Payer perspective. A
stochastic analysis using bootstrap re-sampling was conducted to
generate 95% conﬁdence intervals completed by one-way sensi-
tivity analyses on treatment response to etanercept at 12 weeks,
length of free treatment period, costs of visits, number of hospi-
talisations, discount rates. RESULTS: Over ten years, the QALYs
gained were respectively for NST, efalizumab, etanercept 25 mg
and 50 mg: 0.82, 1.09, 1.35 and 1.46. Costs per patient were
respectively €34,091, €41,797, €36,437 and €38,572. The incre-
mental cost-effectiveness ratio (ICER) compared to NST was
€4,404/QALY for etanercept 25 mg biw, €6,982/QALY for etan-
ercept 50 mg biw and €29,001 for efalizumab. For both etaner-
cept dosages, the ICER obtained from sensitivity analysis varied
from cost-saving to €20,000/QALY. Etanercept (25 mg and
50 mg) is cost-saving compared to efalizumab and sensitivity
analysis performed conﬁrmed this result. CONCLUSIONS: In
patients with moderate-to-severe plaque psoriasis, intermittent
therapy with etanercept was more cost-effective than continuous
therapy with efalizumab and than NST within French setting
care.
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OBJECTIVES: Age-related macular degeneration (AMD) is one
of the most common eye diseases causing vision loss in western
industrial nations. In Austria, about 25,000 people experience
blindness in one or both eyes due to AMD. The incidence aver-
ages 3000 to 4000 people. The purpose of this pharmacoeco-
nomic analysis was to evaluate the cost-effectiveness of the
treatment of AMD with Ranibizumab versus Verteporﬁn.
METHODS: The analysis was conducted using a Markov
Model designed to be ﬂexible to target populations and was
adapted to Austrian situation. Clinical data included in the
model is based on three clinical trials (MARINA, ANCHOR and
PIER). Evaluation of the effectiveness of therapeutic alternatives
was determined by ‘Vision Years’ and ‘QALYs’. The period
under consideration was 10 years and the analysis was per-
formed from the perspective of the Austrian health care system.
Costs are represented using data from 2007. Treatment paths,
resource consumption, costs as well as mortality data have been
adapted for Austria. RESULTS: Within the 10-year period under
consideration, the costs per QALY for Ranibizumab amount
to €9,267 and to €8,795 for Verteporﬁn. Treatment with
Ranibizumab leads to a QALY of 4.2, that with Verteporﬁne
to a QALY of 3.91. The incremental cost-effectiveness-ratio
(ICER) is €15,647. The costs per Vision Year amounts to
13,641€ (2.85 VY) for Ranibizumab and €21,351 (1.61VY) in
the Verteporﬁne-group. The incremental cost-effectiveness-ratio
(ICER) is €3,642. Sensitivity analyses—deterministic and
probabilistic—demonstrated the robustness of the model results.
CONCLUSIONS: The study suggests that in Austria, the treat-
ment of age-related macular degeneration with Ranibizumab is a
cost-effective strategy.
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OBJECTIVES: To compare the lifetime costs and consequences
of liberating patients from spectacles after cataract surgery, by
implanting multifocal IOLs (ReSTOR® or ARRAY-SA40®)
versus a monofocal IOL. METHODS: A Markov model was
created to follow a 69-year old patient cohort from cataract
surgery until death. Prevalence rates of patients not needing
spectacles after cataract surgery were obtained from a random-
ized clinical trial (ARRAY-SA40® versus monofocal) pooled with
a cohort of ReSTOR® patients. Resource utilization, estimated
from a Dutch survey, included surgery, IOLs, spectacles, visits to
ophthalmologists and optic centers, transportation, and time lost
by patients. Economic perspectives were those of Society and
Sick Funds (SF). Dutch mortality rates were introduced into the
model. Discount rates were applied. Sensitivity analyses were
performed. RESULTS: A total of 86.4% of patients implanted
with ReSTOR® were spectacle-free compared to 8.5% with
monofocal and 8.1% with ARRAY-SA40®. On average, 1.2
pairs of spectacles were purchased after ReSTOR® implantation,
versus 7.6 after ARRAY-SA40® or the monofocal. Surgical costs
were €3740 for ReSTOR® and ARRAY-SA40® and €2140 for
the monofocal. From the societal perspective, total undiscounted
cost estimates were €5514 with ReSTOR® compared to €7568
with ARRAY-SA40® and 6526 with the monofocal. With a 4%
discount rate these costs became €5425, €6944 and €5740,
respectively. From the SF perspective, total undiscounted cost
estimates were €2423 with ReSTOR®, €2616 with ARRAY-
SA40 and €2615 with monofocal IOLs. With a 4% discount
these costs became €2415, €2556 and €2555, respectively. Costs
and intervals between spectacle replacements were the most sen-
sitive parameters. CONCLUSIONS: From both the societal and
SF perspectives, discounted and undiscounted savings achieved
by liberating patients from spectacles counterbalanced the ini-
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